Concord Biotech
Concord Biotech Ltd, a leading biopharmaceutical company headquartered in India, has established itself as a key player in the global biotechnology industry since its inception in 2000. With a strong focus on the development and manufacturing of biopharmaceuticals, the company operates primarily in India and has expanded its reach to various international markets. Specialising in the production of biosimilars and active pharmaceutical ingredients (APIs), Concord Biotech is renowned for its commitment to quality and innovation. The company’s core products include a range of biosimilars that cater to therapeutic areas such as oncology and autoimmune diseases, setting them apart through rigorous research and development processes. Recognised for its significant contributions to the biopharmaceutical sector, Concord Biotech has achieved notable milestones, including successful product launches and strategic partnerships, solidifying its position as a trusted name in the industry.
DitchCarbon Score
How does Concord Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Concord Biotech's score of 15 is higher than 88% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Concord Biotech's reported carbon emissions
In 2024, Concord Biotech reported total carbon emissions of approximately 56,740,860 kg CO2e, comprising 14,340,180 kg CO2e from Scope 1 and 42,409,680 kg CO2e from Scope 2. The company has maintained consistent emissions levels, with Scope 1 emissions remaining stable at about 13,460,580 kg CO2e in both 2022 and 2023, while Scope 2 emissions showed a slight increase from 39,507,900 kg CO2e in 2022 to 42,409,680 kg CO2e in 2024. Concord Biotech has not set specific reduction targets or climate pledges, indicating a potential area for future commitment. The absence of Scope 3 emissions suggests a focus on direct operational emissions, but the company may benefit from expanding its climate strategy to encompass broader supply chain impacts. Overall, while the company has not outlined formal reduction initiatives, its emissions data reflects a need for enhanced climate action and transparency in its environmental commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 13,460,580 | 00,000,000 | 00,000,000 |
| Scope 2 | 39,507,900 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Concord Biotech is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
